Literature DB >> 12473838

HIV type 1 group M clades infecting subjects from rural villages in equatorial rain forests of Cameroon.

Ping Zhong1, Sherri Burda, Mateusz Urbanski, Henriette Kenfack, Marcel Tongo, Leo Heyndrickx, Aubin Nanfack, Judith Shang, Lucy Agyingi, Susan Zolla-Pazner, Leopold Zekeng, Phillipe Nyambi.   

Abstract

Though the HIV-1 subtypes infecting patients living in urban and semi-urban areas in Cameroon have been reported, information on the subtypes infecting patients in rural villages is lacking. To begin to understand the diversity of the HIV-1 group M subtypes infecting persons living in rural villages in the equatorial rain forest regions of Cameroon, 49 plasma samples from 14 rural villages in four provinces of Cameroon were analyzed using heteroduplex mobility analysis (HMA), DNA sequencing, and phylogenetic tree analysis on the basis of env C2V5, gag, or pol regions. Sixty-one percent of the group M infections were clade A or CRF02_AG-like as subtyped by env and gag. Of the remaining group M infections, 12% were either A or CRF02_AG-like or CRF01_AE-like in recombination with other clades; 25% were infections that were entirely non-A or non-CRF02_AG-like; and 2% were CRF11_cpx. The HIV-1 group M clades identified included A, D, F (F2), G, and H. The CRF strains identified were CRF02_AG-like, CRF01_AE-like, and CRF11_cpx. Two new intersubtype recombinant infections, H/G and A/F2, were identified. This study suggests that the HIV-1 diversity in rural villages in the equatorial rain forest of Cameroon is at least as broad as has been observed in major cities of Cameroon and that multiple HIV-1 group M subtypes are infecting persons living in the countryside of Cameroon.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12473838     DOI: 10.1097/00126334-200212150-00007

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  17 in total

1.  The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Authors:  Miroslaw K Gorny; Kathy Revesz; Constance Williams; Barbara Volsky; Mark K Louder; Christopher A Anyangwe; Chavdar Krachmarov; Samuel C Kayman; Abraham Pinter; Arthur Nadas; Phillipe N Nyambi; John R Mascola; Susan Zolla-Pazner
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

2.  Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.

Authors:  Miroslaw K Gorny; Constance Williams; Barbara Volsky; Kathy Revesz; Xiao-Hong Wang; Sherri Burda; Tetsuya Kimura; Frank A J Konings; Arthur Nádas; Christopher A Anyangwe; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes.

Authors:  Surender Khurana; James Needham; Susan Park; Bonnie Mathieson; Michael P Busch; George Nemo; Phillipe Nyambi; Susan Zolla-Pazner; Suman Laal; Joseph Mulenga; Elwyn Chomba; Eric Hunter; Susan Allen; James McIntyre; Indira Hewlett; Sherwin Lee; Shixing Tang; Elliot Cowan; Chris Beyrer; Marcus Altfeld; Xu G Yu; Anatole Tounkara; Ousmane Koita; Anatoli Kamali; Nga Nguyen; Barney S Graham; Deborah Todd; Peter Mugenyi; Omu Anzala; Eduard Sanders; Nzeera Ketter; Patricia Fast; Hana Golding
Journal:  J Acquir Immune Defic Syndr       Date:  2006-11-01       Impact factor: 3.731

4.  Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.

Authors:  Chavdar Krachmarov; Abraham Pinter; William J Honnen; Miroslaw K Gorny; Phillipe N Nyambi; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Short Communication: False Recent Ratio of the Limiting-Antigen Avidity Assay and Viral Load Testing Algorithm Among Cameroonians with Long-Term HIV Infection.

Authors:  Briana A Lynch; Eshan U Patel; Colleen R Courtney; Aubin J Nanfack; Jude Bimela; Xiaohong Wang; Issa Eid; Thomas C Quinn; Oliver Laeyendecker; Phillipe N Nyambi; Ralf Duerr; Andrew D Redd
Journal:  AIDS Res Hum Retroviruses       Date:  2017-08-07       Impact factor: 2.205

6.  A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.

Authors:  Liuzhe Li; Xiao-Hong Wang; Constance Williams; Barbara Volsky; Olivia Steczko; Michael S Seaman; Kalpana Luthra; Phillipe Nyambi; Arthur Nadas; Véronique Giudicelli; Marie-Paule Lefranc; Susan Zolla-Pazner; Miroslaw K Gorny
Journal:  Mol Immunol       Date:  2015-05-18       Impact factor: 4.407

7.  CRF22_01A1 is involved in the emergence of new HIV-1 recombinants in Cameroon.

Authors:  Jiangqin Zhao; Shixing Tang; Viswanath Ragupathy; Durga Gaddam; Xue Wang; Panhe Zhang; Phillipe N Nyambi; Indira Hewlett
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-01       Impact factor: 3.731

8.  Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.

Authors:  Miroslaw K Gorny; Xiao-Hong Wang; Constance Williams; Barbara Volsky; Kathy Revesz; Bradley Witover; Sherri Burda; Mateusz Urbanski; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner; Arthur Nadas
Journal:  Mol Immunol       Date:  2008-10-25       Impact factor: 4.407

9.  The Evolution of HIV-1 Diversity in Rural Cameroon and its Implications in Vaccine Design and Trials.

Authors:  Rebecca Powell; Denis Barengolts; Luzia Mayr; Phillipe Nyambi
Journal:  Viruses       Date:  2010-02-12       Impact factor: 5.048

10.  A heteroduplex assay for the rapid detection of dual Human Immunodeficiency Virus Type 1 infections.

Authors:  Rebecca L R Powell; Mateusz M Urbanski; Phillipe N Nyambi
Journal:  J Virol Methods       Date:  2008-03-07       Impact factor: 2.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.